Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > OICR and MaRS Innovation announce funding for the development of Cellax™, a nanotechnology-based cancer drug

Abstract:
The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.

OICR and MaRS Innovation announce funding for the development of Cellax™, a nanotechnology-based cancer drug

Toronto, Canada | Posted on November 14th, 2012

"Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue," said Dr. Rima Al-awar, Director, OICR's Medicinal Chemistry Platform. "OICR is proud to invest in a technology that has such potential to one day improve quality of life for cancer patients."

Cellax, invented by Dr. Shyh-Dar Li and his research team in OICR's Medicinal Chemistry Platform group, is a drug-polymer conjugate based on Dr. Li's proprietary NanoCMC™ technology. These polymers self-assemble into defined nanoparticles and, when injected, selectively accumulate in tumours. Because of this property, the drug is released where it is most needed, increasing therapeutic benefits and reducing the side effects associated with conventional chemotherapy.

With the new funding, the Cellax team will conduct the pre-clinical manufacturing and toxicology studies necessary to bring Cellax to a clinical trial in cancer patients.

"Tumours are by nature more permeable to nano-sized molecules than normal tissue," says Li. "We are developing Cellax to exploit this weakness. We hope to use the NanoCMC platform to deliver drugs that will build up only in tumours. This would spare patients the side effects associated with less targeted treatments, which damage healthy cells as well as tumours."

Cellax, which is made from biocompatible components, is stable in storage and outperforms conventional chemotherapy in pre-clinical models of human tumours.

OICR is supporting the Cellax project through its Intellectual Property Development and Commercialization (IPDC) Fund, which was established to bridge the gap in the commercialization process between public funding agencies and private investors. All IPDC candidate projects are rigorously reviewed by external subject-specific experts in business and technology.

"MaRS Innovation provided the Cellax project with early-stage funding along with business development and management through our high-touch, embedded model," said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. "MI continues to lead Cellax's commercialization strategy. We believe Cellax meets a clear clinical need within the multibillion-dollar Taxane market, and we anticipate that Cellax will emerge as a significant new player."

####

About Ontario Institute for Cancer Research
OICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation, supported by the Government of Ontario. The annual budget for OICR, its research partners and collaborators exceeds $150 million. This supports more than 1,600 investigators, clinician scientists, research staff and trainees located at its headquarters and in research institutes and academia across the Province of Ontario. It has research hubs in Hamilton, Kingston, London, Ottawa, Thunder Bay and Toronto. OICR has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing. For more information, please visit the website at www.oicr.on.ca

About MaRS Innovation

MaRS Innovation (MI) is the commercialization agent for the exceptional discovery pipeline from 16 leading Ontario academic institutions. As a single-entry point to total member research activity of $1 billion in annual research and development, MI provides an easy gateway for investors and licensees who wish to access technology assets in Ontario. Supported by the Government of Canada through the Networks of Centres of Excellence, by the Government of Ontario through the Ontario Centres of Excellence, and by its member institutions, MI is a transformational partnership that turns research strengths into real commercial opportunities. MI's portfolio includes the most promising assets and advances commercialization into global markets through industry partnerships, licensing and company creation.

For more information, please click here

Contacts:
Ontario Institute for Cancer Research
Contact: Christopher Needles
Manager, Editorial Services and Media Relations

Telephone: 416-673-8505
Mobile: 416-319-5252
Twitter @OICR_news

MaRS Innovation
Elizabeth Monier-Williams
Marketing and Communications Manager

Telephone: 647-260-7850
Mobile: 647-537-9097
Twitter @MaRSInnovation

Copyright © CNW Group Ltd.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Govt.-Legislation/Regulation/Funding/Policy

Novel Rocket Design Flight Tested: New Rocket Propellant and Motor Design Offers High Performance and Safety October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Brookhaven Lab Launches Computational Science Initiative:Leveraging computational science expertise and investments across the Laboratory to tackle "big data" challenges October 22nd, 2014

Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Crystallizing the DNA nanotechnology dream: Scientists have designed the first large DNA crystals with precisely prescribed depths and complex 3D features, which could create revolutionary nanodevices October 20th, 2014

QD Vision Wins Prestigious Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency October 16th, 2014

Beyond LEDs: Brighter, new energy-saving flat panel lights based on carbon nanotubes - Planar light source using a phosphor screen with highly crystalline single-walled carbon nanotubes (SWCNTs) as field emitters demonstrates its potential for energy-efficient lighting device October 14th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE